Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.

[1]  A. Isacchi,et al.  Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. , 2010, Bioorganic & medicinal chemistry.

[2]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[3]  E. Radaelli,et al.  Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. , 2009, Histology and histopathology.

[4]  S. Mustjoki,et al.  Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome‐positive acute lymphoblastic leukaemia , 2009, British journal of haematology.

[5]  H. Mayani,et al.  In vitro biology of human myeloid leukemia. , 2009, Leukemia research.

[6]  Tannishtha Reya,et al.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.

[7]  P. Kearns,et al.  Expression of CD133 on leukemia-initiating cells in childhood ALL. , 2009, Blood.

[8]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[9]  K. Nakayama,et al.  Absence of Skp2 Expression Attenuates Bcr-abl-induced , 2008 .

[10]  L Meijer,et al.  CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases , 2008, Oncogene.

[11]  J. Méndez,et al.  CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. , 2008, Carcinogenesis.

[12]  C. Hudis,et al.  Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[13]  L. Cuppini,et al.  The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells , 2007, Leukemia.

[14]  Richard J. Jones,et al.  Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.

[15]  P. Mahajan,et al.  P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models , 2007, Molecular Cancer Therapeutics.

[16]  Thomas S. Lin,et al.  Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. , 2007, Blood.

[17]  P. Kearns,et al.  Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. , 2007, Blood.

[18]  P. Workman,et al.  A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days , 2006, British Journal of Cancer.

[19]  Qing Xiang,et al.  In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials , 2006, Molecular Cancer Therapeutics.

[20]  G. Shapiro,et al.  Cyclin-dependent kinase pathways as targets for cancer treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Peschel,et al.  Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells , 2006, Annals of Hematology.

[22]  Hitoshi Suzuki,et al.  Thr199 phosphorylation targets nucleophosmin to nuclear speckles and represses pre‐mRNA processing , 2006, FEBS letters.

[23]  J. Diffley,et al.  CDKs Promote DNA Replication Origin Licensing in Human Cells by Protecting Cdc6 from APC/C-Dependent Proteolysis , 2005, Cell.

[24]  Hiroshi Yasui,et al.  Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. , 2005, Blood.

[25]  G. Landberg,et al.  Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome , 2005, European journal of haematology.

[26]  D. Lane,et al.  Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. , 2005, Cancer research.

[27]  J. Whitlock,et al.  Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Giavazzi,et al.  Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo , 2005, British journal of haematology.

[29]  Punit Marathe,et al.  N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4- piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. , 2004, Journal of medicinal chemistry.

[30]  P. Bergsagel,et al.  Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma , 2003, Immunological reviews.

[31]  E. Lam,et al.  Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts. , 2001, Cancer research.

[32]  H. F. Horn,et al.  Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.

[33]  D. Hogge,et al.  Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. , 1998, Blood.

[34]  G. Wagemaker,et al.  Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. , 1996, Blood.

[35]  T. Barbui,et al.  Establishment of human acute myelogenous leukemia lines secreting interleukin‐1β in SCID mice , 1995, International journal of cancer.

[36]  C. Sherr,et al.  The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias. , 2008, Cold Spring Harbor symposia on quantitative biology.

[37]  M. Introna,et al.  Effect of alemtuzumab on neoplastic B cells. , 2004, Haematologica.